Aclaris Therapeutics, Inc.
ACRS
$4.88
-$0.07-1.41%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -0.15% | -35.45% | 5.28% | -2.28% | 84.38% |
| Total Depreciation and Amortization | 0.00% | -7.27% | -3.51% | -10.94% | -10.49% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.85% | 12.36% | -35.13% | 18.98% | -95.66% |
| Change in Net Operating Assets | -150.22% | 428.76% | -19.37% | 139.22% | -94.67% |
| Cash from Operations | -38.21% | -20.12% | -9.40% | 23.47% | -46.08% |
| Capital Expenditure | 45.83% | -4.35% | -9.52% | 51.16% | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -397.50% | -24.98% | 173.34% | -73.55% | 121.60% |
| Cash from Investing | -398.31% | -25.03% | 174.02% | -73.60% | 121.55% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -54.32% | -- | 100.00% | 96.73% | 17.42% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 22.08% | -- | -- | -- |
| Cash from Financing | 2,380.23% | 16.75% | -33,722.22% | 96.73% | -100.37% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 264.27% | -3,527.40% | 97.05% | -185.62% | 125.07% |